What is the ACCME's role in the ER/LA opioid Analgesics REMS?

Last Revised: 
August 27, 2012

The ACCME views the FDA ER/LA Opioid Analgesic  REMS as an important initiative for addressing  a critical public health and patient safety concern. The ACCME believes that accredited CME can be an important factor in the success of this REMS and all REMS that involve continuing professional education. The ACCME is committed to facilitating and supporting accredited education to address the prescription drug abuse epidemic and has worked with the FDA, continuing healthcare education accreditors, and accredited continuing education providers throughout the process of developing and implementing the REMS. The ACCME has made itself available to clarify ACCME policy and to assist all the parties involved in implementing a smooth integration of REMS-compliant CME into accredited CME. As an example, the ACCME has modified the Program and Activity Reporting System (PARS) to accommodate REMS-specific information and the ACCME has agreed to provide the audit function described by the FDA.

You voted 'no'.
Was this useful?